Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSLV-132 in Primary Sjogren's Syndrome
NCT03247686Phase 2Completed
- Sponsor
- Resolve Therapeutics
- Start
- Feb 2017
- Primary completion
- Jul 2018
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of RSLV-132, sponsored by Resolve Therapeutics. Started Feb 2017; status: completed.
02
Drugs
RSLV-132
Beyond the preview
Go deeper on NCT03247686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03247686.